EUVIMEDEUVIMED entdecken
Crossref

Design, synthesis and bioactivity evaluation of a series of quinazolinone derivatives as potent PI3Kγ antagonist

Yuqing Liang, Yanjun Zheng, Junjie Yang, Jiahua Ke, Kui Cheng

Bioorganic & Medicinal Chemistry · 2023

DOI: 10.1016/j.bmc.2023.117261 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic & Medicinal Chemistry, 2023. Verfasst von Yuqing Liang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of New Drug Screening and Guangzhou Key Laboratory of Drug Research for Emerging Virus Prevention and Treatment, …. Hauptthemen laut MEDLINE: Antineoplastic Agents, Leukemia, Neoplasms, Protein Kinase Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province, Guangzhou Science and Technology Program key projects.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeting PI3Kγ would be a useful strategy for treating inflammatory and cancer diseases. However, the development of selective inhibitors of PI3Kγ is very challenging due to the high structural and sequence homology with other PI3K isoforms. A series of quinazolinone derivatives were designed, synthesized and biologically evaluated as PI3Kγ-selective inhibitors. Among all the 28 compounds, compound 9b was found to be the most potent selective inhibitor with IC50 values of 13.11 nM against PI3Kγ kinase. Additionally, compound 9b could generate toxicity on leukemia cells in a panel of 12 different of cancer cell lines with the IC50 value of 2.41 ± 0.11 μM on Jurkat cell. Preliminary mechanism studies indicated that compound 9b through inhibit the activity of PI3K-AKT in human and murine leukemia cells, and activated phosphorylated p38 and phosphorylated ERK presented potent antiproliferative activity, which provided a potent small molecule for further cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsLeukemiaNeoplasmsProtein Kinase InhibitorsQuinazolinonesAnimalsHumansMiceCell ProliferationDrug DesignPhosphatidylinositol 3-KinasesStructure-Activity RelationshipClass Ib Phosphatidylinositol 3-Kinase

Stichwörter der Autor:innen

Anti-cancerPhosphatidylinositol 3-kinase γ (PI3Kγ)Small moleculeStructure-activity relationship

Substanzen

Antineoplastic AgentsPhosphatidylinositol 3-KinasesProtein Kinase InhibitorsQuinazolinonesPIK3CG protein, humanClass Ib Phosphatidylinositol 3-Kinase

Autor:innen und Institutionen

  • Guangdong Provincial Key Laboratory of New Drug Screening and Guangzhou Key Laboratory of Drug Research for Emerging Virus Prevention and Treatment, School of Pharmaceutical Sciences, Southern Medical University, Guangz…

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Guangdong Province
  • Guangzhou Science and Technology Program key projects

Zitieren

APA

Liang, Y., Zheng, Y., Yang, J., Ke, J., & Cheng, K. (2023). Design, synthesis and bioactivity evaluation of a series of quinazolinone derivatives as potent PI3Kγ antagonist. Bioorganic & Medicinal Chemistry. https://doi.org/10.1016/j.bmc.2023.117261

Vancouver

Liang Y, Zheng Y, Yang J, Ke J, Cheng K. Design, synthesis and bioactivity evaluation of a series of quinazolinone derivatives as potent PI3Kγ antagonist. Bioorganic & Medicinal Chemistry. 2023. doi:10.1016/j.bmc.2023.117261

BibTeX
@article{Liang2023,
  author = {Liang, Yuqing and Zheng, Yanjun and Yang, Junjie and Ke, Jiahua and Cheng, Kui},
  title = {Design, synthesis and bioactivity evaluation of a series of quinazolinone derivatives as potent PI3Kγ antagonist},
  journal = {Bioorganic & Medicinal Chemistry},
  year = {2023},
  doi = {10.1016/j.bmc.2023.117261}
}
Kostenlos starten →